Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype
Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variant...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenomics 2019-04, Vol.20 (5), p.311-317 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 317 |
|---|---|
| container_issue | 5 |
| container_start_page | 311 |
| container_title | Pharmacogenomics |
| container_volume | 20 |
| creator | Chaidaroglou, Antigoni Kanellopoulou, Theoni Panopoulos, George Stavridis, George Degiannis, Dimitrios |
| description | Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the
and the
gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. We present the first reported case of a patient with the compounded genotype
and
under treatment with acenocoumarol, and review of other reported cases with analogous genotypic profiles but under treatment with warfarin. |
| doi_str_mv | 10.2217/pgs-2018-0189 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2210003533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2210003533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c251t-d653e8bea39dbe81de71611642219a760983dce3231418f11b66fbf219fa5c483</originalsourceid><addsrcrecordid>eNpdkc9LwzAUx4Mobk6PXiXgxUtcXtKl7XGU-QOFiajgqaTt69bRNbVJmfvvzdj04OGRB_m8L9_3voRcAr8VAsJxu7BMcIiYr_iIDCEMAhbxQBz7PlCCiQDUgJxZu-JcgAr4KRlIHkdyItWQLGffrsM11ltamw11S-x0i72rcloYi5aakuocG5Obfq07U9OqoZq22lXYOLqp3JImny8iieVYUt0U9ONp_poAAyXj6XhKF37WbVs8Jyelri1eHN4Reb-bvSUP7Hl-_5hMn1kuJuBYoSYSowy1jIsMIygwBAXetl821qHaGS9ylEJCAFEJkClVZqX_LPUkDyI5Ijd73bYzXz1al64rm2Nd6wZNb1Ovwzn3y0uPXv9DV6bvGu_OU6EKY1_CU2xP5Z2xtsMybbvKn2KbAt-phamPIN1FkO4i8PzVQbXP1lj80b83lz9ZTn55</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2276797672</pqid></control><display><type>article</type><title>Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype</title><source>MEDLINE</source><source>PubMed Central</source><creator>Chaidaroglou, Antigoni ; Kanellopoulou, Theoni ; Panopoulos, George ; Stavridis, George ; Degiannis, Dimitrios</creator><creatorcontrib>Chaidaroglou, Antigoni ; Kanellopoulou, Theoni ; Panopoulos, George ; Stavridis, George ; Degiannis, Dimitrios</creatorcontrib><description>Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the
and the
gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. We present the first reported case of a patient with the compounded genotype
and
under treatment with acenocoumarol, and review of other reported cases with analogous genotypic profiles but under treatment with warfarin.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2018-0189</identifier><identifier>PMID: 30983536</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject><![CDATA[Acenocoumarol - administration & dosage ; Antagonists ; Anticoagulants ; Anticoagulants - administration & dosage ; Cytochrome ; Cytochrome P-450 CYP2C9 - genetics ; Dosage ; Drug dosages ; Enzymes ; Genotype ; Genotype & phenotype ; Genotypes ; Genotyping ; Haplotypes ; Homozygote ; Humans ; International Normalized Ratio ; Male ; Metabolism ; Middle Aged ; Patients ; Pharmacogenomic Testing ; Polymorphism, Single Nucleotide ; Thromboembolism ; Thromboembolism - blood ; Thromboembolism - genetics ; Thromboembolism - prevention & control ; Vitamin K - antagonists & inhibitors ; Vitamin K Epoxide Reductases - genetics ; Warfarin ; Warfarin - administration & dosage]]></subject><ispartof>Pharmacogenomics, 2019-04, Vol.20 (5), p.311-317</ispartof><rights>Copyright Future Medicine Ltd Apr 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c251t-d653e8bea39dbe81de71611642219a760983dce3231418f11b66fbf219fa5c483</citedby><cites>FETCH-LOGICAL-c251t-d653e8bea39dbe81de71611642219a760983dce3231418f11b66fbf219fa5c483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30983536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaidaroglou, Antigoni</creatorcontrib><creatorcontrib>Kanellopoulou, Theoni</creatorcontrib><creatorcontrib>Panopoulos, George</creatorcontrib><creatorcontrib>Stavridis, George</creatorcontrib><creatorcontrib>Degiannis, Dimitrios</creatorcontrib><title>Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the
and the
gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. We present the first reported case of a patient with the compounded genotype
and
under treatment with acenocoumarol, and review of other reported cases with analogous genotypic profiles but under treatment with warfarin.</description><subject>Acenocoumarol - administration & dosage</subject><subject>Antagonists</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration & dosage</subject><subject>Cytochrome</subject><subject>Cytochrome P-450 CYP2C9 - genetics</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Genotyping</subject><subject>Haplotypes</subject><subject>Homozygote</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Pharmacogenomic Testing</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Thromboembolism</subject><subject>Thromboembolism - blood</subject><subject>Thromboembolism - genetics</subject><subject>Thromboembolism - prevention & control</subject><subject>Vitamin K - antagonists & inhibitors</subject><subject>Vitamin K Epoxide Reductases - genetics</subject><subject>Warfarin</subject><subject>Warfarin - administration & dosage</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkc9LwzAUx4Mobk6PXiXgxUtcXtKl7XGU-QOFiajgqaTt69bRNbVJmfvvzdj04OGRB_m8L9_3voRcAr8VAsJxu7BMcIiYr_iIDCEMAhbxQBz7PlCCiQDUgJxZu-JcgAr4KRlIHkdyItWQLGffrsM11ltamw11S-x0i72rcloYi5aakuocG5Obfq07U9OqoZq22lXYOLqp3JImny8iieVYUt0U9ONp_poAAyXj6XhKF37WbVs8Jyelri1eHN4Reb-bvSUP7Hl-_5hMn1kuJuBYoSYSowy1jIsMIygwBAXetl821qHaGS9ylEJCAFEJkClVZqX_LPUkDyI5Ijd73bYzXz1al64rm2Nd6wZNb1Ovwzn3y0uPXv9DV6bvGu_OU6EKY1_CU2xP5Z2xtsMybbvKn2KbAt-phamPIN1FkO4i8PzVQbXP1lj80b83lz9ZTn55</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Chaidaroglou, Antigoni</creator><creator>Kanellopoulou, Theoni</creator><creator>Panopoulos, George</creator><creator>Stavridis, George</creator><creator>Degiannis, Dimitrios</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype</title><author>Chaidaroglou, Antigoni ; Kanellopoulou, Theoni ; Panopoulos, George ; Stavridis, George ; Degiannis, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c251t-d653e8bea39dbe81de71611642219a760983dce3231418f11b66fbf219fa5c483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acenocoumarol - administration & dosage</topic><topic>Antagonists</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration & dosage</topic><topic>Cytochrome</topic><topic>Cytochrome P-450 CYP2C9 - genetics</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Genotyping</topic><topic>Haplotypes</topic><topic>Homozygote</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Pharmacogenomic Testing</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Thromboembolism</topic><topic>Thromboembolism - blood</topic><topic>Thromboembolism - genetics</topic><topic>Thromboembolism - prevention & control</topic><topic>Vitamin K - antagonists & inhibitors</topic><topic>Vitamin K Epoxide Reductases - genetics</topic><topic>Warfarin</topic><topic>Warfarin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaidaroglou, Antigoni</creatorcontrib><creatorcontrib>Kanellopoulou, Theoni</creatorcontrib><creatorcontrib>Panopoulos, George</creatorcontrib><creatorcontrib>Stavridis, George</creatorcontrib><creatorcontrib>Degiannis, Dimitrios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaidaroglou, Antigoni</au><au>Kanellopoulou, Theoni</au><au>Panopoulos, George</au><au>Stavridis, George</au><au>Degiannis, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2019-04</date><risdate>2019</risdate><volume>20</volume><issue>5</issue><spage>311</spage><epage>317</epage><pages>311-317</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the
and the
gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. We present the first reported case of a patient with the compounded genotype
and
under treatment with acenocoumarol, and review of other reported cases with analogous genotypic profiles but under treatment with warfarin.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30983536</pmid><doi>10.2217/pgs-2018-0189</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2019-04, Vol.20 (5), p.311-317 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2210003533 |
| source | MEDLINE; PubMed Central |
| subjects | Acenocoumarol - administration & dosage Antagonists Anticoagulants Anticoagulants - administration & dosage Cytochrome Cytochrome P-450 CYP2C9 - genetics Dosage Drug dosages Enzymes Genotype Genotype & phenotype Genotypes Genotyping Haplotypes Homozygote Humans International Normalized Ratio Male Metabolism Middle Aged Patients Pharmacogenomic Testing Polymorphism, Single Nucleotide Thromboembolism Thromboembolism - blood Thromboembolism - genetics Thromboembolism - prevention & control Vitamin K - antagonists & inhibitors Vitamin K Epoxide Reductases - genetics Warfarin Warfarin - administration & dosage |
| title | Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C93/3 and VKORC1-1639A/A genotype |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extremely%20low%20therapeutic%20doses%20of%20acenocoumarol%20in%20a%20patient%20with%20CYP2C93/3%20and%20VKORC1-1639A/A%20genotype&rft.jtitle=Pharmacogenomics&rft.au=Chaidaroglou,%20Antigoni&rft.date=2019-04&rft.volume=20&rft.issue=5&rft.spage=311&rft.epage=317&rft.pages=311-317&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2018-0189&rft_dat=%3Cproquest_cross%3E2210003533%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2276797672&rft_id=info:pmid/30983536&rfr_iscdi=true |